BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 16142353)

  • 1. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
    Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
    Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10.
    Hector S; Nava ME; Clark K; Murphy M; Pendyala L
    Cancer Lett; 2007 Jan; 245(1-2):195-204. PubMed ID: 16516375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells.
    Varma R; Hector S; Greco WR; Clark K; Hawthorn L; Porter C; Pendyala L
    Cancer Chemother Pharmacol; 2007 May; 59(6):711-23. PubMed ID: 17021820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants.
    Tummala R; Diegelman P; Hector S; Kramer DL; Clark K; Zagst P; Fetterly G; Porter CW; Pendyala L
    Cancer Chemother Pharmacol; 2011 Feb; 67(2):401-14. PubMed ID: 20443003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance.
    Samimi G; Manorek G; Castel R; Breaux JK; Cheng TC; Berry CC; Los G; Howell SB
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):1-11. PubMed ID: 15378272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.
    Li J; Wood WH; Becker KG; Weeraratna AT; Morin PJ
    Oncogene; 2007 May; 26(20):2860-72. PubMed ID: 17072341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780.
    Solár P; Sytkowski AJ
    Cancer Lett; 2011 Oct; 309(1):11-8. PubMed ID: 21676537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
    Ekblad L; Kjellström J; Johnsson A
    Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstration of differential gene expression between sensitive and resistant ovarian tumor cells by fluorescence differential display-PCR analysis.
    Li L; Luan Y; Li X; Tang B; Zhang W; Li D; Zhao J; Wang G; Ding H; Reed E; Li QQ
    Oncol Rep; 2005 May; 13(5):793-9. PubMed ID: 15809740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microarray-based detection and expression analysis of extracellular matrix proteins in drug‑resistant ovarian cancer cell lines.
    Januchowski R; Zawierucha P; Ruciński M; Zabel M
    Oncol Rep; 2014 Nov; 32(5):1981-90. PubMed ID: 25199881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray.
    Sakamoto M; Kondo A; Kawasaki K; Goto T; Sakamoto H; Miyake K; Koyamatsu Y; Akiya T; Iwabuchi H; Muroya T; Ochiai K; Tanaka T; Kikuchi Y; Tenjin Y
    Hum Cell; 2001 Dec; 14(4):305-15. PubMed ID: 11925933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and gene analysis of an oxaliplatin-resistant colon cancer cell line THC8307/L-OHP.
    Tang H; Liu YJ; Liu M; Li X
    Anticancer Drugs; 2007 Jul; 18(6):633-9. PubMed ID: 17762391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells.
    Sherman-Baust CA; Weeraratna AT; Rangel LB; Pizer ES; Cho KR; Schwartz DR; Shock T; Morin PJ
    Cancer Cell; 2003 Apr; 3(4):377-86. PubMed ID: 12726863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP.
    Rennicke A; Voigt W; Mueller T; Fruehauf A; Schmoll HJ; Beyer C; Dempke W
    Anticancer Res; 2005; 25(2A):1147-55. PubMed ID: 15868958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.